2023-10-30 08:00:00
Diagnosis: BioMérieux invests €80 million in Oxford Nanopore
After announcing a research partnership with Oxford Nanopore Technologies last April, BioMérieux is now preparing to invest 70 million pounds (€80 million) in this British company specializing in molecular detection technologies using nanopores. Nanopore sequencing analyzes long fragments of DNA or RNA. This technology thus makes it possible to characterize pathogens in clinical samples quickly and at low cost.
Very concretely, the two entities want to combine their expertise to develop Oxford Nanopore products intended for in vitro diagnostics. Emphasis will be placed on the diagnosis of infectious diseases. As part of this transaction, bioMérieux and Oxford Nanopore will create an advisory committee, called the IVD Advisory Board, aimed at promoting nanopore technologies in routine clinical use. “This investment will strengthen our partnership with Oxford Nanopore and provide more resources for the development of innovative solutions in the field of in vitro diagnostics”commented Pierre Boulud, the general director of bioMérieux.
VOS INDICES
source
Cell therapy: Alaya.bio acquires the key assets of Ixaka France
Parisian biotech Alaya.bio has just signed an agreement with the French subsidiary of the British biotech Ixaka, specialized in CAR-T immunotherapies, to acquire its assets. The operation includes twelve patent families, preclinical data, an exclusive license on the use of specific biopolymers, laboratories and viral vector bioproduction facilities of Ixaka France, in Villejuif (Val-de-Marne). Ultimately, Alaya.bio hopes to optimize the development, manufacturing and delivery of CAR-T therapies. The amount of the agreement was not disclosed. “Alaya.bio will combine its own research work with the solid proof of concept generated by Ixaka, which demonstrated the platform’s ability to efficiently transduce T cells in vivo”indicated Cécile Bauche, the founder of Alaya.bio.
Founded in 2022, Alaya.bio specializes in ex vivo and in vivo cell engineering. For the past nine months, the biotech has been a resident of Biolabs Paris, a recently inaugurated incubator for young biotechnology companies. Thanks to this operation with Ixaka, the biotech says it is ready to raise funds for the first time, as Renaud Vaillant, the founder and president of Alaya.bio, added: “Alaya.bio will be better equipped than ever to meet the main challenges in the development and commercialization of autologous cell therapies. We will also be able to accelerate ongoing discussions with investors and certain partners. »
BMS agrees with LianBio
BMS obtained the rights to LianBio to develop and commercialize mavacamten in mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand. In exchange, the biotech will receive a one-off payment of $350 million (€332 million). LianBio held the rights to mavacatem in these territories following a licensing agreement signed with MyoKardia, a Californian biotech acquired in 2020 by BMS. Marketed under the name Camzyos, mavacamten is authorized for several indications in cardiology.
Selected for you
1698671257
#BioMérieux #Alaya.bio #BMS
